Evidence in favour
- Participation spans 19 named insiders rather than one filing source.
- The latest qualifying evidence is fresh, dated 05 Aug 2026.
Company insider dossier
Teva Pharma Industries Ltd ADR insider intelligence
TEVA filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.
12/100
Concentrated distribution
89/100 confidence- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Latest evidence
- 5 Aug 2026
Investment committee read
Concentrated distribution
Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.
Review exposure and filing contextDecision risks
- Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Price confirmation map
Weekly price with common-share events
Acquisitions and disposals are aligned to the nearest completed weekly bar.
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal
Market confirmation
Price and trend context
- Latest close
- 35.36 USD
- One-week move
- +1.0%
- Four-week move
- +7.3%
- Fair-value gap
- +80.5%
- Trend signal
- Active
- Relative strength
- 10.2
Directional balance
Controlled event mix
0.0%acquisition
- Acquisition events
- 0
- Disposal events
- 15
- Net value
- -$22.1M
Cadence
Twelve-week filing pressure
Volume shows attention. Controlled events determine direction.
925 May
2401 Jun
108 Jun
115 Jun
022 Jun
029 Jun
006 Jul
013 Jul
020 Jul
027 Jul
703 Aug
010 Aug
Named participants
Insider conviction by person
BARER, SOL JDirector500 events
CRANE, ROSEMARY ADirector500 events
ELSTEIN, AMIRDirector500 events
LICHTENSTEIN, CHENDirector500 events
LIEBERMAN, GERALD MDirector500 events
MIGNONE, ROBERTODirector500 events
NISEN, PERRYDirector500 events
SATCHI-FAINARO, RONITDirector500 events
ZAKS, TAL ZVIDirector281 events
HUGHES, ERIC ASee "Remarks"281 events
JOVER, PLACIDSee "Remarks"281 events
DANIELL, RICHARDEVP, Europe Commercial281 events
Evidence quality
Security and transaction context
Role architecture
Who is participating
Transaction evidence
Auditable TEVA filing ledger
Showing 31 to 54 of 54.
SHIELDS, MATTHEWEVP, Global Operations
DisposalEquity compensation
16195 sharesRestricted Share Units
Not reportedContext evidence
SHIELDS, MATTHEWEVP, Global Operations
AcquisitionCommon equity
16195 sharesOrdinary Shares
Not reportedContext evidence
SHIELDS, MATTHEWEVP, Global Operations
DisposalCommon equity
16195 sharesOrdinary Shares
$532.3KDirectional evidence
BARER, SOL JDirector
AcquisitionEquity compensation
10863 sharesRestricted Share Units
Not reportedContext evidence
CRANE, ROSEMARY ADirector
AcquisitionEquity compensation
7242 sharesRestricted Share Units
Not reportedContext evidence
ELSTEIN, AMIRDirector
AcquisitionEquity compensation
7242 sharesRestricted Share Units
Not reportedContext evidence
LICHTENSTEIN, CHENDirector
AcquisitionEquity compensation
7242 sharesRestricted Share Units
Not reportedContext evidence
LIEBERMAN, GERALD MDirector
AcquisitionEquity compensation
7242 sharesRestricted Share Units
Not reportedContext evidence
MIGNONE, ROBERTODirector
AcquisitionEquity compensation
7242 sharesRestricted Share Units
Not reportedContext evidence
NISEN, PERRYDirector
AcquisitionEquity compensation
7242 sharesRestricted Share Units
Not reportedContext evidence
SATCHI-FAINARO, RONITDirector
AcquisitionEquity compensation
7242 sharesRestricted Share Units
Not reportedContext evidence
ZAKS, TAL ZVIDirector
AcquisitionEquity compensation
7242 sharesRestricted Share Units
Not reportedContext evidence
LIPPMAN, EVANEVP, Business Development
DisposalEquity compensation
11841 sharesRestricted Share Units
Not reportedContext evidence
LIPPMAN, EVANEVP, Business Development
DisposalEquity compensation
74008 sharesRestricted Share Units
Not reportedContext evidence
LIPPMAN, EVANEVP, Business Development
AcquisitionCommon equity
74008 sharesOrdinary Shares
Not reportedContext evidence
LIPPMAN, EVANEVP, Business Development
AcquisitionCommon equity
11841 sharesOrdinary Shares
Not reportedContext evidence
KALIF, ELIYAHU SHARONEVP, Chief Financial Officer
DisposalCommon equity
153251 sharesOrdinary Shares
$5.5MDirectional evidence
LIPPMAN, EVANEVP, Business Development
DisposalCommon equity
35912 sharesOrdinary Shares
$1.3MDirectional evidence
LIPPMAN, EVANEVP, Business Development
DisposalCommon equity
5746 sharesOrdinary Shares
$204.5KDirectional evidence
WEISS, AMIRChief Accounting Officer
DisposalCommon equity
10679 sharesOrdinary Shares
$384.4KDirectional evidence
DANIELL, RICHARDEVP, Europe Commercial
DisposalCommon equity
30000 sharesOrdinary Shares
$1.1MDirectional evidence
SABAG, MARKSee "Remarks"
DisposalCommon equity
144180 sharesOrdinary Shares
$5.0MDirectional evidence
FOX, CHRISTINEEVP, U.S. Commercial
DisposalCommon equity
21258 sharesOrdinary Shares
$750.6KDirectional evidence
SABAG, MARKSee "Remarks"
DisposalCommon equity
62102 sharesOrdinary Shares
$1.9MDirectional evidence
Reading the dossier
Direction and confidence are separate
Conviction
The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.
Confidence
Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.
Disposals
Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.
Price confirmation
The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.
Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.